1
|
Esteva F, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Zautashvili Z, Morar-Bolba G, Li R, Lifirenko I, Rusyn A, Lee S, Yu S, Stebbing J. Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Javrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Komov D, Zautashvili Z, Morar-Bolba G, Li RK, Lifirenko I, Rusyn AV, Lee SJ, Lee SY, Esteva FJ. Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.510] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
510 Background: CT-P6 (C) is a proposed biosimilar to trastuzumab. This trial (NCT02162667) evaluated the similarity of C and trastuzumab in efficacy and safety for HER2+ EBC. Methods: 549 patients with HER2+ EBC were randomized to receive C (n=271) or trastuzumab (n=278) in combination with docetaxel (Cycles 1-4) and 5-fluorouracil, epirubicin, and cyclophosphamide (Cycles 5-8). C or trastuzumab was administered at 8 mg/kg (Cycle 1 only) followed by 6 mg/kg every 3 weeks. The primary endpoint was pathological complete response (pCR) rate at surgery. Secondary endpoints were overall response rate (ORR), PK, PD and safety. After surgery, patients received adjuvant C or trastuzumab to complete a total of 1-year treatment. Results: The pCR rate was 46.8% for C and 50.4% for trastuzumab. The 95% CIs for the risk ratio estimate were within the equivalence margin (0.74, 1.35) in PPS and ITT analyses. Other efficacy endpoints were similar between C and trastuzumab. The proportion of patients with at least 1 treatment-emergent SAE was 6.6% for C and 7.6% for trastuzumab. Only 1 patient in each group withdrew treatment due to significant LVEF decrease. Infusion-related reaction was reported for 8.5% of patients in C and 9.0% of patients in trastuzumab. Conclusions: This study demonstrated the similarity of efficacy in terms of pCR between CT-P6 and trastuzumab in EBC patients. Secondary efficacy endpoints also supported the similarity between CT-P6 and trastuzumab. CT-P6 was well tolerated with a similar safety profile to that of trastuzumab during the neoadjuvant period. Clinical trial information: NCT02162667. [Table: see text]
Collapse
Affiliation(s)
- Justin Stebbing
- Imperial College Healthcare NHS Trust, London, United Kingdom
| | | | | | - Alexey Manikhas
- City Clinical Oncology Dispensary, St. Petersburg, Russian Federation
| | - Vladimir Moiseyenko
- St Petersburg Clinical Center of Specialized Medical Care, St. Petersburg, Russia
| | | | - Edvard Javrid
- N.N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus
| | - Dmytro Boliukh
- Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsya, Ukraine
| | | | | | | | - Dmitry Komov
- Russian Oncology Research Centre Blokhin N.N., Moscow, Russia
| | | | | | - Rubi Khaw Li
- St Luke's Medical Center, Quezon City, Philippines
| | | | | | | | | | | |
Collapse
|
3
|
Filon O, Nechaeva M, Burdaeva O, Vladimirov VI, Lifirenko I, Kovalenko NV, Kopp MV, Matrosova M, Mukhametsina G, Panchenko S, Skopin P, Stroyakovskiy D, Krivorotko P, Shapovalova J, Jelvakova I, Sheveleva L, Abrosimova A, Ivanov R, Tjulandin S. Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20735] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Marina Nechaeva
- Arkhangelsk Regional Clinical Oncologic Dispensary, Arkhangelsk, Russia
| | - Olga Burdaeva
- Arkhangelsk Regional Clinical Oncologic Dispensary, Arkhangelsk, Russia
| | | | | | | | | | | | - Guzel Mukhametsina
- State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia
| | | | - Pavel Skopin
- Republican Oncologic Dispensary, Saransk, Russia
| | | | - Petr Krivorotko
- N.N. Petrov Scientific Reserch Institute of Oncology, St. Petersburg, Russia
| | | | | | - Ludmila Sheveleva
- Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russia
| | | | | | | |
Collapse
|
4
|
Damaraju S, Gorbunova V, Gelmon KA, Garcia Saenz JA, Morales S, Abigerges DY, Canon JL, Lifirenko I, Cohen GL, Jerusalem GHM, Thireau F, Fresco R, Houé V, Press MF, Narasimhan A, Mackey JR. Relationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Vera Gorbunova
- N.N.Blokhin Russian Cancer Research Center, Moscow, Russia
| | | | | | - Serafin Morales
- Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | | | | | | | | | | | | | | | - Vincent Houé
- Translational Research In Oncology, Paris, France
| | | | | | | |
Collapse
|
5
|
Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sørensen P, Nielsen T, Lisby S, Clement PMJ. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12:333-43. [DOI: 10.1016/s1470-2045(11)70034-1] [Citation(s) in RCA: 200] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|